This report examines the need for the the dapivirine monthly ring, its potential contribution to HIV prevention, and the steps that must be taken while the product is clearing initial regulatory approvals to ensure speedy access for women and girls.

Watch this video to learn about the dapivirine vaginal ring and the International Partnership for Microbicide’s next steps to potentially put the product into the hands of women at high risk of HIV.

In a July 13, 2017 press release, the International Partnership for Microbicides (IPM) announces that its application for the monthly dapivirine vaginal ring is under review by the European Medicines Agency (EMA). The release also outlines plans to submit applications to other regulatory authorities in pursuit of licensure.

The findings from an assessment of the feasibility and potential impact of delivering antiretroviral (ARV)-based oral and injectable pre-exposure prophylaxis (PrEP) and vaginal microbicide gels in South Africa are summarized in this brief.